NRichDx

SARS-CoV-2 infection surging in parts of the Boston area based on analysis of viral RNA in wastewater. #Wastewater #Testing #COVIDTesting https://bit.ly/34Aeb7H

‘Cancer doesn’t take a pause,’ amid pandemic, many Americans avoided oncology screenings - in today's The Wall Street Journal. Reliable liquid biopsies needed now more than ever. nRichDX's Revolution System part of the solution. #oncology #cancerscreening #liquidbiopsy https://on.wsj.com/3196HpK

miR Scientific, LLC gets FDA Breakthrough Device designation for its miR Sentinel PCC4 Assay (miR Sentinel Prostate Test). The #liquidbiopsy test analyzes small non-coding RNAs (sncRNA) derived from a urine specimen through a proprietary Statistical Classification Algorithm to classify patients. #cfDNA #prostatecancer https://hubs.li/H0x-qDn0

Urine-based liquid biopsy more effective than urine cytology in bladder cancer detection for UroCAD Assay as published in Clinical Cancer Research, a journal of the American Association for Cancer Research (AACR) #CNV #bladdercancer #liquidbiopsy https://hubs.li/H0xQlmB0

"I am convinced that that the practice of 'liquid first' should be even implemented before tissue biopsy is performed; if so, we may see even more dramatic outcomes." from today's presentation of pilot study data at the IASLC 2020 Lung Cancer Hot Topic: Liquid Biopsy Virtual Conference. #liquidbiopsy #cfDNA #oncology #sampleprep https://hubs.li/H0xmTpZ0

Capping a big week for liquid biopsy, Exact Sciences stock soars on new data around pan-cancer liquid biopsy - overall sensitivity of 86% and specificity of 95% across six cancer types. #liquidbiopsy #cfDNA #oncology https://hubs.ly/H0w_9r00

Not all tumors have the same amount of circulating tumor DNA, says [oncologist] Garon in new TIME article on liquid biopsy, So a negative test for a gene mutation does not definitively rule out the idea that a mutation is present. Get more #cfDNA with nRichDX. https://hubs.li/H0wHKjR0

"it’s possible that negative results aren’t actually negative, but mean instead that there wasn’t enough DNA material to work with." says new article on liquid biopsy in TIME That's the problem that nRichDX solves. Get More cfDNA. #cfDNA #liquidbiopsy https://hubs.li/H0wH9Kb0

Interesting review article from NIH authors on exRNA, #exosomes, and their potential as clinical biomarkers and use in liquid biopsy. #RNA #extracellularvesicles #EVs #liquidbiopsy https://hubs.li/H0wFr270

"Europe is missing out on major opportunities." from new lengthy Position Statement encouraging greater use of oncology biomarkers (and liquid biopsies) in the European Union. #liquidbiopsy #biomarkers #ctDNA #cancer #EU https://hubs.li/H0wyWm-0

Looking for earlier detection of cf/ctDNA, or targets with low allele frequency? Is your sample large enough? Get more cf/ctDNA from the high-sample-volume, high-yield, Revolution System from nRichDX. #liquidbiopsy #ctDNA https://hubs.li/H0wxVC80

Weird 2020 is an extraordinary year for liquid biopsy, with two recent approvals and more tests in the pipeline. See the table in this article for a concise overview. #liquidbiopsy #oncology #sampleprep. https://hubs.li/H0wpn6v0

"The challenge [MRD detection]: the smaller the tumor, the less DNA released from the cancer cells, so the harder it is to detect." says Karen Weintraub in new article in USA Today. A solution is larger sampling volume for higher yield of cf/ctDNA. Check out nRichDX's Revolution System. https://hubs.li/H0vJj0R0 USA TODAY #liquidbiopsy #oncology #sampleprep #cfDNA